Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261.
Division of Life Science, Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong.
J Neurosci. 2023 Mar 8;43(10):1830-1844. doi: 10.1523/JNEUROSCI.0172-22.2023. Epub 2023 Jan 30.
The amyloid precursor protein (APP) is linked to the genetics and pathogenesis of Alzheimer's disease (AD). It is the parent protein of the β-amyloid (Aβ) peptide, the main constituent of the amyloid plaques found in an AD brain. The pathways from APP to Aβ are intensively studied, yet the normal functions of APP itself have generated less interest. We report here that glutamate stimulation of neuronal activity leads to a rapid increase in gene expression. In mouse and human neurons, elevated APP protein changes the structure of the axon initial segment (AIS) where action potentials are initiated. The AIS is shortened in length and shifts away from the cell body. The GCaMP8f Ca reporter confirms the predicted decrease in neuronal activity. NMDA antagonists or knockdown of block the glutamate effects. The actions of APP on the AIS are cell-autonomous; exogenous Aβ, either fibrillar or oligomeric, has no effect. In culture, APP (a familial AD mutation) induces larger AIS changes than wild type APP. Ankyrin G and βIV-spectrin, scaffolding proteins of the AIS, both physically associate with APP, more so in AD brains. Finally, in humans with sporadic AD or in the R1.40 AD mouse model, both females and males, neurons have elevated levels of APP protein that invade the AIS. as , this increased APP is associated with a significant shortening of the AIS. The findings outline a new role for the APP and encourage a reconsideration of its relationship to AD. While the amyloid precursor protein (APP) has long been associated with Alzheimer's disease (AD), the normal functions of the full-length Type I membrane protein have been largely unexplored. We report here that the levels of APP protein increase with neuronal activity. and , modest amounts of excess APP alter the properties of the axon initial segment. The β-amyloid peptide derived from APP is without effect. Consistent with the observed changes in the axon initial segment which would be expected to decrease action potential firing, we show that APP expression depresses neuronal activity. In mouse AD models and human sporadic AD, APP physically associates with the scaffolding proteins of the axon initial segment, suggesting a relationship with AD dementia.
淀粉样前体蛋白 (APP) 与阿尔茨海默病 (AD) 的遗传和发病机制有关。它是β-淀粉样蛋白 (Aβ) 肽的母蛋白,Aβ 是 AD 大脑中发现的淀粉样斑块的主要成分。从 APP 到 Aβ 的途径受到了深入研究,但 APP 本身的正常功能引起的兴趣较少。我们在这里报告说,谷氨酸刺激神经元活动会导致基因表达的快速增加。在小鼠和人类神经元中,升高的 APP 蛋白改变了动作电位起始的轴突起始段 (AIS) 的结构。AIS 的长度缩短,并从细胞体移开。GCaMP8f Ca 报告证实了预测的神经元活动减少。NMDA 拮抗剂或敲低 可阻断谷氨酸的作用。APP 对 AIS 的作用是细胞自主的;外源性 Aβ,无论是纤维状还是寡聚体,都没有影响。在培养物中,APP(家族性 AD 突变)引起的 AIS 变化大于野生型 APP。锚蛋白 G 和 βIV- spectrin,AIS 的支架蛋白,都与 APP 物理结合,在 AD 脑中更为明显。最后,在散发 AD 的人类或 R1.40 AD 小鼠模型中,无论是雌性还是雄性,神经元的 APP 蛋白水平升高,入侵 AIS。与 ,这种增加的 APP 与 AIS 的显著缩短有关。这些发现概述了 APP 的新作用,并鼓励重新考虑其与 AD 的关系。尽管淀粉样前体蛋白 (APP) 长期以来一直与阿尔茨海默病 (AD) 相关,但全长 I 型膜蛋白的正常功能在很大程度上仍未得到探索。我们在这里报告说,APP 蛋白水平随神经元活动而增加。而且,少量多余的 APP 改变了轴突起始段的性质。源自 APP 的 β-淀粉样蛋白没有影响。与预期会降低动作电位发射的轴突起始段的观察到的变化一致,我们表明 APP 表达抑制神经元活动。在小鼠 AD 模型和人类散发 AD 中,APP 与轴突起始段的支架蛋白物理结合,提示与 AD 痴呆有关。